Sutro (STRO) presents preclinical ADC data at AACR meeting

Sutro Biopharma (STRO) showcased preclinical data on its antibody-drug conjugate (ADC) pipeline during the AACR meeting. This event is significant as it highlights the company's progress in developing targeted therapies. The ADC approaches are designed to improve treatment outcomes for cancer patients, which could impact investor sentiment and future capital flow. However, specific numerical results or significant data points were not disclosed in the presentation.